keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
Published 2 years ago • 368 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
3:15
phase ii study of petosemtamab and pembrolizumab for recurrent/metastatic hnscc
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
1:09
the future role of immunotherapy in head and neck cancers
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
2:37
pembrolizumab is effective in recurrent, metastatic squamous cell carcinomas of the head and neck
-
7:56
keynote-048: progression post next line for r/m hnscc
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
3:12
novel immunotherapy approaches in metastatic head and neck cancer
-
4:06
immunotherapy for head and neck cancer treatment
-
9:31
study in patients with recurrent ir metastatic head & neck squamous cell carcinoma
-
0:58
development of a vaccine for pre-treated head & neck squamous cell carcinoma
-
2:55
tacti-002 and tacti-003: eftilagimod alpha for metastatic head and neck squamous cell carcinoma